OncoMatch/Clinical Trials/NCT06735495
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Is NCT06735495 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CD19&CD22 bispecific CAR-T cells for b-cell lymphoblastic leukemia/lymphoma.
Treatment: CD19&CD22 bispecific CAR-T cells — This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD22 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive by FCM or immunohistochemistry)
The results of FCM or immunohistochemical detection of tumor antigen (CD 19 / CD 22) were positive.
Required: CD22 overexpression (positive by FCM or immunohistochemistry)
The results of FCM or immunohistochemical detection of tumor antigen (CD 19 / CD 22) were positive.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: monoclonal antibody against CD20 — B-cell lymphoma
Subject must have received prior adequate treatment, including at least: a monoclonal antibody against CD 20
Must have received: anthracycline — B-cell lymphoma
combination chemotherapy containing an anthracycline drug agent
Lab requirements
Blood counts
hgb≥70g/l (transfusible)
Kidney function
creatinine ≤1.5xuln
Liver function
total bilirubin ≤1.5xuln; alt and ast≤2.5x uln
Cardiac function
left ventricular ejection fraction >50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify